Pfizer’s Hold Rating: Balancing Policy Uncertainties and Long-Term Growth Prospects

Citi analyst Geoff Meacham has maintained their neutral stance on PFE stock, giving a Hold rating yesterday.

Geoff Meacham has given his Hold rating due to a combination of factors that reflect both opportunities and challenges for Pfizer. One of the primary considerations is the policy landscape, where Pfizer’s exposure is seen as comparable to its peers. The uncertainties surrounding the implementation of the Most Favored Nation (MFN) policy and potential tariff impacts are notable, but Pfizer’s focus on operational efficiencies and business development remains strong.
Additionally, while Pfizer’s product Vyndaqel is a significant growth driver, the company faces challenges from upcoming loss of exclusivity (LOE) events that could impact revenue. Despite these challenges, Pfizer is optimistic about its long-term pipeline and business development prospects, especially beyond 2030. The expected share price return of 9.3% suggests moderate growth potential, aligning with the Hold rating as Pfizer navigates these complex factors.

Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Pfizer, and Bristol-Myers Squibb. According to TipRanks, Meacham has an average return of 1.0% and a 50.21% success rate on recommended stocks.

In another report released yesterday, Bernstein also assigned a Hold rating to the stock with a $30.00 price target.